Key Insights

Highlights

Success Rate

89% trial completion (above average)

Published Results

42 trials with published results (22%)

Research Maturity

123 completed trials (65% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

8.0%

15 terminated out of 188 trials

Success Rate

89.1%

+2.6% vs benchmark

Late-Stage Pipeline

28%

53 trials in Phase 3/4

Results Transparency

34%

42 of 123 completed with results

Key Signals

42 with results89% success15 terminated

Data Visualizations

Phase Distribution

108Total
Not Applicable (20)
P 1 (11)
P 2 (24)
P 3 (28)
P 4 (25)

Trial Status

Completed123
Unknown27
Terminated15
Recruiting12
Not Yet Recruiting5
Withdrawn5

Trial Success Rate

89.1%

Benchmark: 86.5%

Based on 123 completed trials

Clinical Trials (188)

Showing 20 of 20 trials
NCT04261712Phase 2TerminatedPrimary

A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)

NCT06930625Phase 3RecruitingPrimary

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs

NCT05131100CompletedPrimary

Korean Regulatory Post Marketing Surveillance for Somavert

NCT04837040Phase 3TerminatedPrimary

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly

NCT05192382Phase 3TerminatedPrimary

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)

NCT07583563RecruitingPrimary

An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly

NCT07663318Phase 1Not Yet RecruitingPrimary

A Phase 1 Study to Evaluate the Relative Bioavailability of Octreotide Acetate Tablets(T25) Compared to MYCAPSSA® and The Food Effect on Pharmacokinetics Of Octreotide Acetate Tablets(T25)

NCT07659912Not Yet RecruitingPrimary

Direct Versus Video Laryngoscopy in Patients With Acromegaly

NCT07641179Phase 2Not Yet RecruitingPrimary

A Study to Evaluate MAR002 for Acromegaly

NCT04349839CompletedPrimary

ACRODAT Prospective Evaluation Study

NCT00461188RecruitingPrimary

Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA

NCT00921609CompletedPrimary

Peri-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly

NCT07037420Phase 2RecruitingPrimary

ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly

NCT07195175Phase 1RecruitingPrimary

Study of MAR002 in Healthy Men

NCT04125836Phase 3CompletedPrimary

A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

NCT04066569Not ApplicableCompletedPrimary

Reproducibility and Utility of OGTT in Acromegaly

NCT05364944Phase 1TerminatedPrimary

A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

NCT07179926Recruiting

Effects of Pasireotide Lar Therapy on Bone Metabolism

NCT07100587Not ApplicableCompletedPrimary

Ketogenic vs. Mediterranean Diet on Metabolic and Hormonal Parameters in Patients With Active Acromegaly

NCT01809808CompletedPrimary

A Prospective Study of Outcome After Therapy for Acromegaly

Scroll to load more

Research Network

Activity Timeline